Hot sale MK 2866(841205-47-8) from Professional Sarm Manufacturer- Phcoker Chemical
MK2866 Description
MK-2866, also known as Ostarine or Enobosarm, is in class of drugs called SARMS, which an investigational selective androgen receptor modulators with Ki of 3.8 nM, and is tissue-selective for anabolic organs. MK-2866 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. It be used for the treatment of diseases such as muscle atrophy and osteoporosis. And MK-2866 has been used by athletes to assist in training and increase physical stamina and fitness. Elderly men and women who took modest doses of Ostarine for 12 weeks grew 3 pounds of muscle and lost a pound of fat, with no changes to diet or exercise.
MK-2866 Specifications
Product Name
| |
Chemical Name
|
MK-2866 (GTx-024), Ostarine, MK 2866, S-22, ENOBOSARM, (S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide, HMS3654E16, BCP02391, CS-0562, DB12078, O3571H3R8N, AC-30221, AJ-92121, (S)-Ostarine, GTx 024, (2S)-3-(4-Cyanophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide
|
Brand Name
|
No data for available
|
Drug Class
|
Aromatics; Intermediates; Pharmaceuticals; Hormone Drugs; SARMs(Selective androgen receptor modulator); Inhibitors
|
CAS Number
|
841205-47-8
|
InChIKey
|
JNGVJMBLXIUVRD-SFHVURJKSA-N
|
Molecular Formula
|
C19H14F3N3O3
|
Molecular Weight
|
389.3279696
|
Monoisotopic Mass
|
389.099 g/mol
|
Melting Point
|
132 to 136 °C (270 to 277 °F)
|
Freezing Point
|
No data for available
|
Biological Half-Life
|
24 hours
|
Color
|
A crystalline solid
|
Solubility
|
25°C) * In vitro DMSO 78 mg/mL (200.34 mM); Ethanol78 mg/mL (200.34 mM); Water<1 mg/mL (<1 mM); In vivo 1% DMSO+30% polyethylene glycol+1% Tween 805 mg/mL
|
Storage Temperature
|
3 years at -20°C
|
MK-2866 Application
|
Mk-2866 Ostarine capsules/tablets for bodybuilding, cutting, recomping etc
|
MK-2866 (841205-47-8) video
https://vimeo.com/309416213
Comments
Post a Comment